148 related articles for article (PubMed ID: 31078910)
1. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
Kumar C; P T V L; Arunachalam A
Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
[TBL] [Abstract][Full Text] [Related]
2. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine.
Nilov D; Maluchenko N; Kurgina T; Pushkarev S; Lys A; Kutuzov M; Gerasimova N; Feofanov A; Švedas V; Lavrik O; Studitsky VM
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245127
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel PARP-1 inhibitors using tandem
Bhatnagar A; Nath V; Kumar N; Kumar V
J Biomol Struct Dyn; 2024 Apr; 42(7):3396-3409. PubMed ID: 37216358
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
[TBL] [Abstract][Full Text] [Related]
7. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
8. Modeling of the Enzyme-Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1.
Nilov DK; Pushkarev SV; Gushchina IV; Manasaryan GA; Kirsanov KI; Švedas VK
Biochemistry (Mosc); 2020 Jan; 85(1):99-107. PubMed ID: 32079521
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Mechanistic Inhibitory Discrepancies of Novel Halogen and Alkyl Di-Substituted Oxadiazole-Based Dibenzo-Azepine-Dione Derivatives on Poly (ADP-Ribose) Polymerase-1.
Okunlola FO; Soremekun OS; Olotu FA; Soliman MES
Chem Biodivers; 2021 Jan; 18(1):e2000802. PubMed ID: 33289285
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold.
Elmasry GF; Aly EE; Awadallah FM; El-Moghazy SM
Bioorg Chem; 2019 Jun; 87():655-666. PubMed ID: 30952061
[TBL] [Abstract][Full Text] [Related]
11. Active site fingerprinting and pharmacophore screening strategies for the identification of dual inhibitors of protein kinase C (ΡΚCβ) and poly (ADP-ribose) polymerase-1 (PARP-1).
Chadha N; Silakari O
Mol Divers; 2016 Aug; 20(3):747-61. PubMed ID: 27216445
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer.
Okunlola FO; Olotu FA; Soliman MES
J Biomol Struct Dyn; 2022; 40(21):10878-10886. PubMed ID: 34463214
[TBL] [Abstract][Full Text] [Related]
13. 2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors.
Nilov DK; Yashina KI; Gushchina IV; Zakharenko AL; Sukhanova MV; Lavrik OI; Švedas VK
Biochemistry (Mosc); 2018 Feb; 83(2):152-158. PubMed ID: 29618301
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
Zhou Y; Tang S; Chen T; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
[TBL] [Abstract][Full Text] [Related]
15. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
[TBL] [Abstract][Full Text] [Related]
16. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
17. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
Kumar C; Lakshmi PTV; Arunachalam A
J Mol Graph Model; 2021 Nov; 108():107919. PubMed ID: 34304979
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
[TBL] [Abstract][Full Text] [Related]
19. Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design.
Khizer H; Maryam A; Ansari A; Ahmad MS; Khalid RR
Arch Biochem Biophys; 2024 Jun; 756():110010. PubMed ID: 38642632
[TBL] [Abstract][Full Text] [Related]
20. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
